Trial to Evaluate the Efficacy and Safety of LYT-100 Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis

Deupirfenidone · שלב 3

מזהה רישום
NCT07284602
שלב
שלב 3
סטטוס
מגייס
תרופה / התערבות
Deupirfenidone
ממן
PureTech
התחלה
2026-04
מספר משתתפים
1100
מיקומים
10

על הניסוי

This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant nor their study team will know which study drug participants are on. Participants will be in the study for up to approximately 3 years. During the first year, participants visit the study site up to t

צפו ב-NCT07284602 ב-ClinicalTrials.gov ←

הבהרה רפואית. דף זה מסכם נתוני ניסוי ציבוריים עבור NCT07284602 למידע בלבד. אין זה ייעוץ רפואי, המלצה או הצעה להשתתף. אמתו פרטים ב-ClinicalTrials.gov ומול רופא מוסמך.